Christopher Gibson Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Christopher Gibson is Chief Executive Officer of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 954,229 shares of RXRX, which is worth approximately $5.24 Million. The most recent transaction as insider was on Jul 07, 2022, when has been sold 18,500 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 954K

11.75% 3M change

25.12% 12M change

Total Value Held $5.24 Million

Christopher Gibson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 07 2022	BUY Conversion of derivative security	-	18,500 Added 3.27%	547,404 Class A Common Stock
Jun 21 2022	SELL Bona fide gift	-	3,000 Reduced 0.55%	543,805 Class A Common Stock
Jun 02 2022	SELL Open market or private sale	$242,506 $6.11 p/Share	39,690 Reduced 7.14%	516,268 Class A Common Stock
Jun 02 2022	BUY Exercise of conversion of derivative security	$77,500 $2.48 p/Share	31,250 Added 5.49%	537,458 Class A Common Stock
Jun 02 2022	BUY Conversion of derivative security	-	18,500 Added 3.34%	534,768 Class A Common Stock
May 19 2022	SELL Bona fide gift	-	12,000 Reduced 2.15%	546,805 Class A Common Stock
May 16 2022	SELL Payment of exercise price or tax liability	$32,682 $5.67 p/Share	5,764 Reduced 1.13%	506,208 Class A Common Stock
May 12 2022	SELL Bona fide gift	-	12,000 Reduced 2.1%	558,805 Class A Common Stock
May 05 2022	SELL Open market or private sale	$119,140 $6.44 p/Share	18,500 Reduced 3.49%	511,972 Class A Common Stock
May 05 2022	BUY Conversion of derivative security	-	18,500 Added 3.37%	530,472 Class A Common Stock
May 04 2022	SELL Open market or private sale	$206,577 $6.49 p/Share	31,830 Reduced 5.85%	511,972 Class A Common Stock
May 04 2022	BUY Exercise of conversion of derivative security	$77,500 $2.48 p/Share	31,250 Added 5.61%	525,302 Class A Common Stock
May 04 2022	BUY Conversion of derivative security	-	18,500 Added 3.37%	530,472 Class A Common Stock
Apr 29 2022	SELL Open market or private sale	$235,653 $6.19 p/Share	38,070 Reduced 7.15%	494,052 Class A Common Stock
Apr 29 2022	BUY Exercise of conversion of derivative security	$109,155 $2.48 p/Share	44,014 Added 7.89%	513,622 Class A Common Stock
Apr 29 2022	BUY Conversion of derivative security	-	18,500 Added 3.48%	512,552 Class A Common Stock
Apr 28 2022	SELL Open market or private sale	$229,014 $6.09 p/Share	37,605 Reduced 7.41%	469,608 Class A Common Stock
Apr 28 2022	BUY Exercise of conversion of derivative security	$109,145 $2.48 p/Share	44,010 Added 8.26%	488,713 Class A Common Stock
Apr 28 2022	BUY Conversion of derivative security	-	18,500 Added 3.65%	488,108 Class A Common Stock
Apr 25 2022	SELL Bona fide gift	-	12,000 Reduced 2.06%	570,805 Class A Common Stock
Apr 25 2022	SELL Bona fide gift	-	12,000 Reduced 2.63%	444,703 Class A Common Stock
Apr 25 2022	BUY Conversion of derivative security	-	12,000 Added 2.56%	456,703 Class A Common Stock
Apr 22 2022	SELL Open market or private sale	$229,236 $6.04 p/Share	37,953 Reduced 7.86%	444,703 Class A Common Stock
Apr 22 2022	BUY Exercise of conversion of derivative security	$109,145 $2.48 p/Share	44,010 Added 8.66%	464,156 Class A Common Stock
Apr 22 2022	BUY Conversion of derivative security	-	18,500 Added 3.84%	463,203 Class A Common Stock

Christopher Gibson

Chief Executive Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account